



The Illinois Medical Bulletin



Intensive Glycemic Control and Mortality in Critically Ill Patients: A Review of Pivotal Evidence

¹A. Buckley, ²A. Burke

^{1,2} University of Illinois College of Medicine

Corresponding Email : buckleymd9838737@gmail.com

Article History :

Received date : 2017/10/12
Revised date : 2017/11/28
Accepted date : 2017/12/09
Published date : 2018/01/13



Copyright: © by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Introduction: Hyperglycemia is a frequent complication in critically ill patients and is independently associated with adverse outcomes. This observation led to a period of intense clinical investigation to determine whether aggressive normalization of blood glucose levels using intensive insulin therapy could improve survival in the intensive care unit (ICU).

Literature Review: A review of the pivotal literature reveals a remarkable scientific arc. A landmark single-center trial initiated a paradigm shift by reporting a dramatic reduction in mortality with intensive glycemic control compared to conventional management. This finding prompted widespread, enthusiastic adoption of tight glucose control protocols in ICUs globally. However, subsequent trials in different patient populations reported more modest or no survival benefit, while consistently highlighting a significant increase in the risk of severe hypoglycemia. This clinical equipoise was ultimately addressed by a large, international, multi-center randomized trial. This definitive study demonstrated that tight glucose control did not

reduce mortality; conversely, it resulted in a significant increase in mortality compared to a moderate control strategy, alongside a much higher incidence of hypoglycemia.

Conclusion: The body of evidence illustrates a complete scientific cycle of discovery, validation, and refutation. It demonstrates that the initial promise of intensive glycemic control was not substantiated in broader, more pragmatic trials and revealed an important safety risk. This research fundamentally reshaped clinical practice, establishing a safer, more moderate approach to glucose management in the critically ill.

Keywords: Intensive Glycemic Control, Critical Illness, Hyperglycemia, Intensive Care Unit (ICU), Mortality.

INTRODUCTION

The development of hyperglycemia in patients admitted to the intensive care unit (ICU) is a common phenomenon, driven by the profound metabolic and endocrine stress response to severe illness. For many years, this "stress hyperglycemia" was often viewed as a potentially adaptive physiological response and was therefore managed permissively. However, a growing body of observational data consistently linked elevated blood glucose levels with increased risks of infection, organ failure, and mortality, suggesting that hyperglycemia was more maladaptive than beneficial.

This understanding prompted a fundamental question: could therapeutic intervention to normalize blood glucose levels improve outcomes in the critically ill? This question sparked a period of intense clinical investigation that led to a dramatic, albeit temporary, change in worldwide clinical practice. This literature review aims to synthesise the pivotal scientific publications that examined the relationship between intensive glycemic control and mortality in critically ill patients, chronicling a remarkable journey of discovery, debate, and eventual practice reversal.

LITERATURE REVIEW

The investigation into the benefits of intensive glycemic control in the ICU is best understood as a narrative that unfolded through a series of high-impact clinical trials.

The field was revolutionised by a single-center, randomized controlled trial conducted in a surgical ICU population. This landmark study, published by Van den Berghe et al. (2001),

compared a strategy of intensive insulin therapy, targeting blood glucose levels between 80 and 110 mg/dL (4.4 to 6.1 mmol/L), to conventional treatment. The results were striking and unexpected: intensive control reduced ICU mortality by over 40%. The reported benefits extended to reductions in sepsis, acute renal failure, and the need for blood transfusions. The impact of this study was immediate and profound, leading to the rapid and widespread adoption of tight glycemic control protocols in ICUs around the globe, as it appeared to be a highly effective life-saving intervention.

Following this initial success, the same research group sought to determine if this benefit extended to patients in a medical ICU. The subsequent trial found a more modest effect, with a significant mortality benefit only observed in the subgroup of patients who had a longer ICU stay of three or more days (Van den Berghe et al., 2006). This introduced an element of nuance and suggested that the benefit might not be universal across all critically ill populations.

As other investigators attempted to implement intensive insulin protocols, a major safety concern began to emerge. Multiple studies and clinical experiences highlighted a consistent and significant increase in the rate of severe hypoglycemia (dangerously low blood glucose) associated with tight control strategies. A multi-center German trial known as the VISEP study was even stopped prematurely due to an increased incidence of hypoglycemia in the intensive therapy group, without any evidence of a survival benefit (Brunkhorst et al., 2008). This created significant clinical equipoise: was the potential benefit of tight glucose control worth the very real risk of iatrogenic hypoglycemia?

This critical question was definitively answered by a large, pragmatic, international randomized trial known as the NICE-SUGAR study. Involving over 6,000 patients from ICUs in multiple countries, it was designed to provide a robust answer generalizable to typical ICU practice. The study compared tight glucose control (target 81-108 mg/dL) with a moderate approach (target <180 mg/dL). The results were conclusive and surprising. The investigators found that tight glycemic control did not reduce mortality at 90 days; instead, it led to a statistically significant 2.6% absolute increase in mortality. As expected, severe hypoglycemia was far more common in the intensive-control group (The NICE-SUGAR Study Investigators, 2009). This trial effectively refuted the findings of the initial single-center study and demonstrated that, for a general ICU population, the strategy was not only ineffective but harmful.

CONCLUSION

The collective body of literature examining the relationship between intensive glycemic control and mortality in the critically ill provides a powerful lesson in evidence-based medicine. It chronicles a complete scientific arc, from a single, paradigm-shifting study that inspired global practice change, through a period of uncertain replication and emerging safety signals, to a definitive, large-scale trial that overturned the initial findings.

The evidence clearly demonstrates that while the initial promise of tight glycemic control was immense, the strategy failed to confer a survival benefit in broader, more heterogeneous patient populations and significantly increased the risk of harm from severe hypoglycemia. This research fundamentally reshaped the standard of care, leading to the abandonment of aggressive glycemic targets and the adoption of a more moderate, safety-focused approach to managing hyperglycemia in the ICU. It stands as a landmark example of the critical importance of robust, multi-center evidence in guiding clinical practice.

REFERENCES

Brunkhorst, F.M., Engel, C., Bloos, F., Meier-Hellmann, A., Ragaller, M., Weiler, N., Moerer, O., Gruendling, M., Oppert, M., Grond, S., Olthoff, D., Jaschinski, U., John, S., Rossaint, R., Welte, T., Schaefer, M., Kern, P., Kuhnt, E., Kiehntopf, M., Hartog, C., Natanson, C., Loeffler, M. and Reinhart, K. (2008) 'Intensive insulin therapy and pentastarch resuscitation in severe sepsis', *New England Journal of Medicine*, 358(2), pp. 125-139.

Krinsley, J.S. (2004) 'Effect of an intensive glucose management protocol on the mortality of critically ill adult patients', *Mayo Clinic Proceedings*, 79(8), pp. 992-1000.

The NICE-SUGAR Study Investigators. (2009) 'Intensive versus conventional glucose control in critically ill patients', *New England Journal of Medicine*, 360(13), pp. 1283-1297.

Van den Berghe, G., Wouters, P., Weekers, F., Verwaest, C., Bruyninckx, F., Schetz, M., Vlasselaers, D., Ferdinande, P., Lauwers, P. and Bouillon, R. (2001) 'Intensive insulin therapy in critically ill patients', *New England Journal of Medicine*, 345(19), pp. 1359-1367.

Van den Berghe, G., Wilmer, A., Hermans, G., Meersseman, W., Wouters, P.J., Milants, I., Van Wijngaerden, E., Bobbaers, H. and Bouillon, R. (2006) 'Intensive insulin therapy in the medical ICU', *New England Journal of Medicine*, 354(5), pp. 449-461.

